Venclexta

Assess for level of tumor lysis syndrome risk; provide prophylactic hydration and anti-hyperuricemics prior to 1^st dose. Swallow whole. Take with food and water at the same time each day. CLL/SLL (initiate with 5-week ramp-up): 20mg once daily for Week 1, then 50mg once daily for Week 2, then 100mg once daily for Week 3, then 200mg once daily for Week 4, then 400mg once daily for Week 5. Monotherapy: continue 400mg once daily until disease progression or unacceptable toxicity. In combination with rituximab: initiate rituximab after 5-week ramp-up phase and has received venetoclax 400mg for 7 days; give rituximab on Day 1 of each 28-day cycle for 6 cycles and continue venetoclax 400mg once daily for 24 months from Cycle 1 Day 1 of rituximab (see full labeling). In combination with obinutuzumab: initiate obinutuzumab on Cycle 1 Day 1 (see full labeling); on Cycle 1 Day 22, initiate venetoclax 5-week ramp up schedule, then continue venetoclax 400mg once daily from Cycle 3 Day 1 until the last day of Cycle 12. AML: confirm WBC is <25×10⁹/L prior to initiation; initiate combination therapy on Cycle 1 Day 1. Ramp-up phase: 100mg on Day 1, then 200mg on Day 2, followed by 400mg on Day 3; on Day 4 and beyond, continue 400mg once daily of each 28-day cycle (in combination with azacitidine or decitabine) or 600mg once daily of each 28-day cycle (in combination with low-dose cytarabine); continue until disease progression or unacceptable toxicity. Severe hepatic impairment (Child-Pugh C): reduce dose by 50%; monitor. Concomitant strong or moderate CYP3A inhibitors or P-gp inhibitors, dose modifications for toxicities, TLS prophylaxis: see full labeling.